Amgen Reports post-marketing Data for Tezepelumab in Hidradenitis suppurativa

Amgen today announced post-marketing results for tezepelumab in patients with hidradenitis suppurativa. The study demonstrated that tezepelumab reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of hidradenitis suppurativa and support the continued development of tezepelumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.